


## Recombinant Human Insulin-like Growth Factor Binding Protein 2/IGFBP2 (C-hFc)

Catalog No: BP067

<b>Description</b>	Recombinant Human Insulin-like Growth Factor Binding Protein 2 is produced by Human 293 Cells. The target gene encoding A36-Q325 is expressed with a hFc tag at the C terminus.																								
<b>Expression System</b>	Human																								
<b>Alternative name</b>	BP2; IBP2; IBP-2; IGF-binding protein 2; IGFBP2; IGFBP-2; IGF-BP53; insulin-like growth factor binding protein 2 (36kD); insulin-like growth factor binding protein 2, 36kDa; insulin-like growth factor-binding protein 2																								
<b>Accession No.</b>	P18065																								
<b>Predicted Molecular Weight</b>	61.5kDa																								
<b>Apparent Molecular Weight</b>	IGFBP2 protein appeared at 64kDa in a reducing SDS-PAGE gel																								
<b>Quality Control</b>	Purity: greater than 95% as determined by reducing SDS-PAGE. Endotoxin: less than 0.1 ng/µg (1 EU/µg) as determined by TAL test.																								
<b>Formulation</b>	PBS, pH 7.4																								
<b>Shipping</b>	The product is shipped on dry ice pack. Upon receipt, store it immediately at the temperature listed below.																								
<b>Storage</b>	Store at $\leq$ 70°C, stable for 6 months after receipt. Store at $\leq$ 70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.																								
<b>Background</b>	Insulin-like Growth Factor Binding Protein 2 (IGFBP2) is a member of IGF binding protein superfamily. IGFBP2 is expressed in a number of tissues during development. The highest expression level is found in the central nervous system. In adults, high expression levels are also detected in the central nervous system as well as reproductive tissues. IGFBP2 prolongs the half-life of the IGFs and have been shown to either inhibit or stimulate the growth-promoting effects of the IGFs on cell culture. In addition, IGFBP2 is overexpressed in many malignancies and is often correlated with an increasingly malignant status of the tumor, indicating potential involvement of IGFBP2 in tumorigenesis.																								
<b>SDS-PAGE</b>	<table border="0"> <tr> <td>KDa</td> <td>M</td> <td>1</td> </tr> <tr> <td>116</td> <td></td> <td></td> </tr> <tr> <td>66.2</td> <td></td> <td></td> </tr> <tr> <td>45</td> <td></td> <td></td> </tr> <tr> <td>35</td> <td></td> <td></td> </tr> <tr> <td>25</td> <td></td> <td></td> </tr> <tr> <td>18.4</td> <td></td> <td></td> </tr> <tr> <td>14.4</td> <td></td> <td></td> </tr> </table>  <p>M: Marker 1: Sample in reducing condition</p>	KDa	M	1	116			66.2			45			35			25			18.4			14.4		
KDa	M	1																							
116																									
66.2																									
45																									
35																									
25																									
18.4																									
14.4																									